CRISPR Therapeutics
Cambridge · Founded 2013
About CRISPR Therapeutics
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Company Facts
- Founded: 2013
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $957.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (Mar 2026)
- Ticker: nasdaq:CRSP
- Website: crisprtx.com
- Phone: 141794589327
Industries & Categories
Biopharma, Biotechnology, Genetics, Medical
Social Profiles
Canonical: https://fsome.com/organization/crispr-therapeutics-44986 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.